PHAS

Q: What is the price of PhaseBio Pharmaceuticals (PHAS) today?

The current price of PhaseBio Pharmaceuticals (PHAS) is $ 0.00, representing a 0% gain over the past year. The stock began the year trading around $ 0.00 and is currently priced at $ 0.00. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

Q: When does PhaseBio Pharmaceuticals (PHAS) pay dividends?

PhaseBio Pharmaceuticals (PHAS) did not pay dividends over the past year.

PhaseBio Pharmaceuticals Inc.

Price

$ -

return (12m)

0.00%

p/e

-0.02

p/bv

-0.02

DIVIDEND YIELD

0.00%

PHAS price

PhaseBio Pharmaceuticals

If you had invested

exposure

years ago

7 days

30 days

6 months

YTD

1 year

5 years

10 years

15 years

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment PHAS

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.00%

3 months

0.00%

1 year

0.00%

2 years

0.00%

5 years

0.00%

10 years

0.00%

Fundamentals PHAS

review the fundamentals of PhaseBio Pharmaceuticals shares

P/E

-0.02

Sector: -4.17 Industry: -4.17

P/S (PSR)

Sector: -4.38 Industry: -4.38

P/BV

-0.02

Sector: 1.92 Industry: 1.92

DIVIDEND YIELD (DY)

0.00%

Sector: - Industry: -

ROA

-463.95%

Sector: -66.78% Industry: -66.78%

ROE

87.60%

Sector: -69.59% Industry: -69.59%

ROIC

Sector: -2,913.84% Industry: -2,913.84%

NET MARGIN

100.00%

Sector: -40.86% Industry: -40.86%

GROSS MARGIN

-3.35%

Sector: 36.26% Industry: 36.26%

OPERATING MARGIN

-30.52%

Sector: -39.84% Industry: -39.84%

EV/EBITDA

0.07

Sector: -4.31 Industry: -4.31

EV/EBIT

0.07

Sector: -4.38 Industry: -4.38

PRICE-TO-ASSETS

0.09

Sector: 1.43 Industry: 1.43

BVPS

-2.39

Sector: 1.84 Industry: 1.84

EPS

-2.09

Sector: -2.21 Industry: -2.21

EQUITY-TO-ASSETS RATIO

-5.30

Sector: 0.42 Industry: 0.42

LIABILITIES / ASSETS

-5.30

Sector: 0.39 Industry: 0.39

CAGR REVENUE 5 YEARS

0.00%

Sector: - Industry: -

CAGR PROFIT 5 YEARS

-4.74%

Sector: - Industry: -

Fundamentals PHAS

DRAG THE FRAME TO SEE MORE DATA

Stock Comparison Tool

DRAG THE FRAME TO SEE MORE DATA

	p/e	p/bv	ROE	dy	market cap	net margin
JNJ	25.65	6.65	25.92%	2.32%	$ 539.72 B	21.83%
PFE	19.57	1.62	8.29%	6.68%	$ 146.58 B	11.83%
ABBV	106.01	-58.28	-54.98%	3.10%	$ 385.36 B	5.79%
NVO	10.68	6.45	60.40%	4.09%	$ 202.51 B	37.15%
MRK	32.85	6.39	19.45%	2.80%	$ 293.48 B	13.59%
AZN	27.68	6.07	21.93%	1.72%	$ 287.60 B	17.19%
GILD	18.12	7.13	39.33%	2.37%	$ 166.96 B	30.99%
BMY	16.02	5.80	36.19%	4.37%	$ 116.53 B	15.01%
ZTS	12.27	10.03	81.75%	2.64%	$ 32.42 B	27.79%
REGN	14.45	2.03	14.08%	0.58%	$ 63.94 B	29.65%
HALO	22.51	35.75	158.82%	0.00%	$ 7.85 B	23.13%
AMGN	23.32	19.79	84.87%	2.87%	$ 181.87 B	20.96%
MCK	19.02	-108.61	-570.98%	0.43%	$ 90.58 B	1.18%
HRMY	12.58	2.01	16.00%	0.00%	$ 1.83 B	16.20%
VRTX	26.20	5.87	22.41%	0.00%	$ 113.68 B	35.51%
CAH	29.74	-17.31	-58.20%	1.04%	$ 46.25 B	0.62%
ADMA	11.39	4.82	42.37%	0.00%	$ 1.88 B	32.43%

Stock vs Indice Comparison Tool

If you had invested

years ago

2 years

5 years

10 years

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

PHAS Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Inc.

Average Investor10 user rating

4.0 (0 people)

United States

24 years

Founded: 2002

2018

Time since IPO - 8 years

50

Employees

PhaseBio Pharmaceuticals Inc. (United States) is listed on the Nasdaq and has a market capitalization of $1.97 Million, with shareholders equity totaling $-117.40 Millions.

The company employs approximately 50 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, PhaseBio Pharmaceuticals Inc. reported $-10.00 Millions in revenue, generating net income of $-102.84 Millions.

Key financial metrics include a P/E ratio of -0.02, a price-to-book (P/B) ratio of -0.02, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker PHAS.

Market cap

$ 1.97 Million

Net worth

$ -117.40 Millions

$ -117,398,000.00

Assets

$ 22.17 Millions

$ 22,166,000.00

Total Shares Outstanding

49.18 Millions

49,182,000

Average Daily Trading Volume

$ 2.21 Millions

$ 2,205,483.50

Sector

Health Care

Industry

Biotechnology

PHAS

PHAS revenue and profits

Financial Results PHAS

DRAG THE FRAME TO SEE MORE DATA

PHAS cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more stocks

BFRA - Biofrontera

$ - -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$ 742.44 3,60% (12M)

P/E

19.02

0.43%

ROE

-570.98%

P/BV

-108.61

CAH - Cardinal Health

$ 196.80 28,88% (12M)

P/E

29.74

1.04%

ROE

-58.20%

P/BV

-17.31

JNJ - Johnson & Johnson

$ 225.33 50,10% (12M)

P/E

25.65

2.32%

ROE

25.92%

P/BV

6.65

MRK - Merck & Co.

$ 118.72 60,08% (12M)

P/E

32.85

2.80%

ROE

19.45%

P/BV

6.39

AZN - AstraZeneca

$ 185.67 31,33% (12M)

P/E

27.68

1.72%

ROE

21.93%

P/BV

6.07

ABBV - AbbVie

$ 217.72 20,70% (12M)

P/E

106.01

3.10%

ROE

-54.98%

P/BV

-58.28

NVO - Novo Nordisk

$ 45.58 --33,17% (12M)

P/E

10.68

4.09%

ROE

60.40%

P/BV

6.45

BFRA - Biofrontera

$ - -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$ 742.44 3,60% (12 M)

P/L

19.02

0.43%

ROE

-570.98%

P/VP

-108.61

CAH - Cardinal Health

$ 196.80 28,88% (12 M)

P/L

29.74

1.04%

ROE

-58.20%

P/VP

-17.31

JNJ - Johnson & Johnson

$ 225.33 50,10% (12 M)

P/L

25.65

2.32%

ROE

25.92%

P/VP

6.65

MRK - Merck & Co.

$ 118.72 60,08% (12 M)

P/L

32.85

2.80%

ROE

19.45%

P/VP

6.39

AZN - AstraZeneca

$ 185.67 31,33% (12 M)

P/L

27.68

1.72%

ROE

21.93%

P/VP

6.07

ABBV - AbbVie

$ 217.72 20,70% (12 M)

P/L

106.01

3.10%

ROE

-54.98%

P/VP

-58.28

NVO - Novo Nordisk

$ 45.58 --33,17% (12 M)

P/L

10.68

4.09%

ROE

60.40%

P/VP

6.45

Frequently Asked Questions

What is the price of PhaseBio Pharmaceuticals (PHAS) today?

The current price of PhaseBio Pharmaceuticals (PHAS) is $ 0.00, representing a 0% gain over the past year. The stock began the year trading around $ 0.00 and is currently priced at $ 0.00. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

When does PhaseBio Pharmaceuticals (PHAS) pay dividends?

PhaseBio Pharmaceuticals (PHAS) did not pay dividends over the past year.

Is PhaseBio Pharmaceuticals (PHAS) a good investment?

PhaseBio Pharmaceuticals (PHAS) is currently trading at $ 0.00 with a P/E ratio of -0.02. This represents a -2% premium compared to its historical average P/E. Over the past year, the stock has gained 0 and paid $ 0.00 in dividends, resulting in a dividend yield of 0.00%. The total shareholder return over the same period was 0.00%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy PhaseBio Pharmaceuticals (PHAS) stock?

You can buy PhaseBio Pharmaceuticals (PHAS) shares through any brokerage account that provides access to U.S. stock exchanges. After opening and funding your account, simply search for the ticker symbol PHAS and place a buy order. Before investing, consider factors such as your financial goals, risk tolerance, and overall portfolio allocation.

How much would 100 shares of PhaseBio Pharmaceuticals (PHAS) yield today?

Over the past month, PhaseBio Pharmaceuticals (PHAS) has returned 0.00% — 0.00% over the past year, and 0.00% over the past five years, including price appreciation and dividends.

In the last 12 months, the company paid a total of 0.00 per share in dividends, resulting in a dividend yield of 0.00%.

If you were to purchase 100 shares of PhaseBio Pharmaceuticals (PHAS) today at the current price of $ 0.00 your total investment would be $ 0.00.

Based on historical performance, the investment would have grown to approximately:

$ 0.00 after 1 year
$ 0.00 after 5 years
$ 0.00 after 10 years

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

PHAS

PhaseBio Pharmaceuticals Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment PHAS

review the fundamentals of PhaseBio Pharmaceuticals shares

P/E

P/S (PSR)

P/BV

DIVIDEND YIELD (DY)

ROA

ROE

ROIC

NET MARGIN

GROSS MARGIN

OPERATING MARGIN

EV/EBITDA

EV/EBIT

PRICE-TO-ASSETS

BVPS

EPS

EQUITY-TO-ASSETS RATIO

LIABILITIES / ASSETS

CAGR REVENUE 5 YEARS

CAGR PROFIT 5 YEARS

current DY: 0.00%

5-year average DY: 0.00%

ABOUT PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Inc.

United States

24 years

2018

50

PROFIT X PRICE PHAS

Financial Results PHAS

PHAS cash flow

Asset, Revenue and Profit Growth - PHAS

PHAS balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

MRK - Merck & Co.

AZN - AstraZeneca

ABBV - AbbVie

NVO - Novo Nordisk

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

MRK - Merck & Co.

AZN - AstraZeneca

ABBV - AbbVie

NVO - Novo Nordisk

Frequently Asked Questions